Kristin Khalaf - Concepedia

Author

Kristin Khalaf

Allergan (United States)

Also Known As

K Khalaf, K. Khalaf, K.M. Khalaf, Khalaf, K., Kristin Khalaf, Kristin M Khalaf, Kristin M. Khalaf

Publications

535

Citations

H-Index

Concepts

All Affiliations

Allergan (United States)University of Arizona Adelphi Group (United Kingdom)Allergan (Ireland)University College London

About

Kristin Khalaf is an author at Allergan (United States) specializing in medicine, quality of life, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	64
2	Quality Of Life	2	2	64
3	Rehabilitation	1	1	33
4	Urogynecology	1	1	33
5	Outcomes Research	1	1	33

Kristin Khalaf

Publications

310

Citations

H-Index

Page 1

	Year	Citations
Impact of urinary incontinence on healthcare resource utilization, health‐related quality of life and productivity in patients with overactive bladder Derek Tang, Danielle Colayco, Kristin Khalaf, British Journal of Urology	2013	98
Lower Urinary Tract Symptom Prevalence and Management Among Patients with Multiple Sclerosis Kristin Khalaf, Karin S. Coyne, Denise Globe, International Journal of MS Care	2014	54
The impact of lower urinary tract symptoms on health‐related quality of life among patients with multiple sclerosis Kristin Khalaf, Karin S. Coyne, Denise Globe, Neurourology and Urodynamics	2014	52
Mapping EQ-5D Utility Scores from the Incontinence Quality of Life Questionnaire among Patients with Neurogenic and Idiopathic Overactive Bladder Stephen Kay, Keith Tolley, Danielle Colayco, Value in Health Quality Of LifeEq-5d Utility ScoresUrologyLife AssessmentVoiding Dysfunction	2013	33
Psychometric Performance of the Incontinence Quality-of-Life Questionnaire Among Patients With Overactive Bladder and Urinary Incontinence Donald L. Patrick, Kristin Khalaf, Roger R. Dmochowski, Clinical Therapeutics Quality Of LifeLife AssessmentUrologyVoiding DysfunctionUrinary Incontinence	2013	31
Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison Nick Freemantle, David A. Ginsberg, Rachael McCool, BMJ Open	2016	17
OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales Nick Freemantle, Kristin Khalaf, C. Loveman, The European Journal of Health Economics	2015	14
Patient‐reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity Emmanuel Chartier‐Kastler, Eric Rovner, Zsolt Hepp, Neurourology and Urodynamics	2015	11

Page 1